The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor

European Journal of Cancer

Volumn 37, Issue 15, 2001, Pages 1930-1937

  Philpott, M ^a   Ching, L M ^a   Baguley, B C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

CD14; Interleukin 1; Lipopolysaccharide; NF kappaB; Okadaic acid; Phorbol ester

Indexed keywords

4 O METHYLPHORBOL 13 ACETATE 12 MYRISTATE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTIBODY; ANTIBODY MEM 18; ANTINEOPLASTIC AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CYTOKINE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MITOFLAXONE; OKADAIC ACID; POLYMYXIN B; PROTEIN SUBUNIT; SALICYLATE SODIUM; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SYNTHESIS;

ANTIGENS, CD14; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; NF-KAPPA B; OKADAIC ACID; SALICYLIC ACID; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES; XANTHONES;

EID: 0034812637     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00210-6     Document Type: Article

References (39)

1. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids
2. Flavone acetic acid - Preclinical and clinical activity
3. Impact on tumour perfusion measured by dynamic magnetic resonance imaging (MRI), in the phase 1 trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
4. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
5. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs
6. Inhibition of tumour blood flow
7. Stimulation of macrophage tumoricidal activity by 5,6-dimethylxanthenone-4-acetic acid, a potent analogue of the antitumor agent flavone-8-acetic acid
8. Immunomodulatory actions of xanthenone anticancer agents
9. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid
10. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
11. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy
12. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
13. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice
14. Positive and negative regulation of I kappa B kinase activity through IKK beta subunit phosphorylation
15. Identification and characterization of an I-kappa-b kinase
16. NAK is an I kappa B kinase-activating kinase
17. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein
18. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling
19. Bacterial lipopolysaccharide activates nuclear factor-kappa B through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes
20. Induction of STAT and NF kappa B activation by the antitumour agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line
21. The effect of 5,6-dimethylxanthenone-4-acetic acid on tumor necrosis factor production by human immune cells
22. Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488)
23. Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution
24. Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism
25. Differential utilization of Janus kinase-signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-alpha
26. Gram-negative endotoxin - An extraordinary lipid with profound effects on eukaryotic signal transduction
27. Human CD14 mediates recognition and phagocytosis of apoptotic cells
28. Deacylated lipopolysaccharide inhibits plasminogen activator inhibitor-1, prostacyclin, and prostaglandin E2 induction by lipopolysaccharide but not by tumor necrosis factor-alpha
29. Inhibition of lipopolysaccharide-induced macrophage tumor necrosis factor-α synthesis by polymyxin B sulfate
30. Effects of pretreatment with protein kinase C activators on macrophage activation for tumor cytotoxicity, secretion of tumor necrosis factor, and its mRNA expression
31. Stimulation of tumor necrosis factor-alpha production in human monocytes by inhibitors of protein phosphatase-1 and phosphatase-2A
32. Okadaic acid is a potent inducer of AP-1, NF-kappa B, and tumor necrosis factor-alpha in human B lymphocytes
33. Inhibition of NF-kappa B by sodium salicylate and aspirin
34. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I kappa B kinase-beta
35. IL-6 Inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice
36. A cytokine-responsive I-kappa-B kinase that activates the transcription factor NF-kappa-B
37. NF-kappa-B-inducing kinase activates IKK-alpha by phosphorylation of ser-176
38. The multisubunit I-kappa-B kinase complex shows random sequential kinetics and is activated by the C-terminal domain of I-kappa-B-alpha
39. IFN and virus-inducible expression of an immediate early gene, crg-2/IP-10, and a delayed gene, I-A alpha in astrocytes and microglia